A study of therapeutic equivalence of mometasone lotion and Elomet lotion in seborrheic dermatitis of scalp
Phase 2
- Conditions
- Seborrheic dermatitis of scalpSeborrheic dermatitis of scalp, mometasone lotion, Elomet lotion
- Registration Number
- TCTR20220215001
- Lead Sponsor
- HOE Pharmaceuticals Sdn. Bhd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Age 18-80 years
2. Diagnosed with seborrheic dermatitis of scalp
3. New onset dermatitis or recurrent seborrheic dermatitis in which can withdraw topical steroid and Moisturizer for 2 weeks, oral medication for 4 weeks before joining this project
4.No other medications usage during the project
5.Can follow up at 2nd and 4th week of the project
6. Inform and consent
Exclusion Criteria
1. History of allergic reaction to component used in the project
2. Ongoing bacterial, fungal or viral skin infection
3. Pregnancy or breastfeeding
4. History of allergic reaction to topical or systemic steroid
5. Deny or withdraw during attending the project
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical severity of seborrheic dermatitis of scalp 2nd and 4th week after using mometasone lotion Modified clinical severity score
- Secondary Outcome Measures
Name Time Method Patient Satisfaction Score, side effect of lotion 2nd and 4th week after using mometasone lotion Patient reported outcome using a visual analogue scale and note the side effect